Literature DB >> 21482767

Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist.

Claire L Newton1, Adele M Whay, Craig A McArdle, Meilin Zhang, Chris J van Koppen, Ruud van de Lagemaat, Deborah L Segaloff, Robert P Millar.   

Abstract

Naturally occurring mutations of G protein-coupled receptors (GPCRs) causing misfolding and failure to traffic to the cell surface can result in disease states. Some small-molecule orthosteric ligands can rescue such misfolded receptors, presumably by facilitating their correct folding and shuttling to the plasma membrane. Here we show that a cell-permeant, allosterically binding small-molecule agonist (Org 42599) rescues the folding and cell surface expression, and therefore target cell signaling, of mutant human luteinizing hormone (LH) receptors (A593P and S616Y) that cause Leydig cell hypoplasia in man. Both mutant receptors were retained in the cytoplasm whereas WT receptor localized at the cell membrane, and binding of LH to cells expressing the mutant receptors was markedly lower than to those expressing the WT receptor. Incubation with Org 42599 increased mutant receptor expression, cell surface localization, and the proportion of mutant receptor in the mature glycosylated form. Importantly, although LH stimulated little (S616Y) or no (A593P) activation of cells expressing mutant receptors, incubation of cells with Org 42599 facilitated rescue of expression and stimulation by the native ligand, LH. Although Org 42599 could activate these receptors, it could not displace (125)I-labeled human LH binding to the WT receptor, indicating that it acts in an allosteric manner. Here we demonstrate a small-molecule GPCR allosteric agonist that functionally rescues intracellularly retained mutant LH receptors by facilitating their cell surface expression. This approach may have application for treatment of infertile patients bearing such mutations and, more broadly, for other misfolded GPCR mutants resulting in human pathologic processes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482767      PMCID: PMC3084114          DOI: 10.1073/pnas.1015723108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function.

Authors:  I T Huhtaniemi
Journal:  Endocr Rev       Date:  2000-10       Impact factor: 19.871

2.  Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation.

Authors:  Ulla E Petäjä-Repo; Mireille Hogue; Suparna Bhalla; André Laperrière; Jean-Pierre Morello; Michel Bouvier
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

3.  The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction.

Authors:  N C R van Straten; G G Schoonus-Gerritsma; R G van Someren; J Draaijer; A E P Adang; C M Timmers; R G J M Hanssen; C A A van Boeckel
Journal:  Chembiochem       Date:  2002-10-04       Impact factor: 3.164

4.  A splice site mutation combined with a novel missense mutation of LHCGR cause male pseudohermaphroditism.

Authors:  Jie Qiao; Bing Han; Bing-Li Liu; Xia Chen; Ying Ru; Kai-Xiang Cheng; Fu-Guo Chen; Shuang-Xia Zhao; Jun Liang; Ying-Li Lu; Jin-Feng Tang; Yi-Xin Wu; Wan-Ling Wu; Jia-Lun Chen; Ming-Dao Chen; Huai-Dong Song
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

5.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

Authors:  J P Morello; A Salahpour; A Laperrière; V Bernier; M F Arthus; M Lonergan; U Petäjä-Repo; S Angers; D Morin; D G Bichet; M Bouvier
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 6.  Nephrogenic diabetes insipidus.

Authors:  J P Morello; D G Bichet
Journal:  Annu Rev Physiol       Date:  2001       Impact factor: 19.318

7.  Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target.

Authors:  Jo Ann Janovick; Guadalupe Maya-Nunez; P Michael Conn
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

8.  Intracellularly located misfolded glycoprotein hormone receptors associate with different chaperone proteins than their cognate wild-type receptors.

Authors:  D Mizrachi; D L Segaloff
Journal:  Mol Endocrinol       Date:  2004-04-22

9.  Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa.

Authors:  Syed M Noorwez; Vladimir Kuksa; Yoshikazu Imanishi; Li Zhu; Sławomir Filipek; Krzysztof Palczewski; Shalesh Kaushal
Journal:  J Biol Chem       Date:  2003-02-01       Impact factor: 5.157

Review 10.  Gonadotropin-releasing hormone receptors.

Authors:  Robert P Millar; Zhi-Liang Lu; Adam J Pawson; Colleen A Flanagan; Kevin Morgan; Stuart R Maudsley
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

View more
  28 in total

1.  The iodide-transport-defect-causing mutation R124H: a δ-amino group at position 124 is critical for maturation and trafficking of the Na+/I- symporter.

Authors:  Viktoriya Paroder; Juan P Nicola; Christopher S Ginter; Nancy Carrasco
Journal:  J Cell Sci       Date:  2013-05-20       Impact factor: 5.285

Review 2.  Small GTPase regulation of GPCR anterograde trafficking.

Authors:  Guansong Wang; Guangyu Wu
Journal:  Trends Pharmacol Sci       Date:  2011-10-17       Impact factor: 14.819

3.  Functional rescue of Kallmann syndrome-associated prokineticin receptor 2 (PKR2) mutants deficient in trafficking.

Authors:  Dan-Na Chen; Yan-Tao Ma; Huadie Liu; Qun-Yong Zhou; Jia-Da Li
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

Review 4.  Regulation of G protein-coupled receptors by allosteric ligands.

Authors:  J Robert Lane; Alaa Abdul-Ridha; Meritxell Canals
Journal:  ACS Chem Neurosci       Date:  2013-02-21       Impact factor: 4.418

Review 5.  Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

Authors:  Alfredo Ulloa-Aguirre; Teresa Zariñán; James A Dias; P Michael Conn
Journal:  Mol Cell Endocrinol       Date:  2013-06-24       Impact factor: 4.102

Review 6.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

Review 7.  Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

8.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

Review 9.  Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.

Authors:  Cassandra Koole; Emilia E Savage; Arthur Christopoulos; Laurence J Miller; Patrick M Sexton; Denise Wootten
Journal:  Mol Endocrinol       Date:  2013-07-17

10.  Retinitis pigmentosa mutants provide insight into the role of the N-terminal cap in rhodopsin folding, structure, and function.

Authors:  Chikwado A Opefi; Kieron South; Christopher A Reynolds; Steven O Smith; Philip J Reeves
Journal:  J Biol Chem       Date:  2013-10-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.